[go: up one dir, main page]

RU2021118423A - Hypertonic ophthalmic ointment - Google Patents

Hypertonic ophthalmic ointment Download PDF

Info

Publication number
RU2021118423A
RU2021118423A RU2021118423A RU2021118423A RU2021118423A RU 2021118423 A RU2021118423 A RU 2021118423A RU 2021118423 A RU2021118423 A RU 2021118423A RU 2021118423 A RU2021118423 A RU 2021118423A RU 2021118423 A RU2021118423 A RU 2021118423A
Authority
RU
Russia
Prior art keywords
ointment according
paragraphs
ointment
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
RU2021118423A
Other languages
Russian (ru)
Inventor
Винченцо ОРФЕО
Original Assignee
Винченцо ОРФЕО
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Винченцо ОРФЕО filed Critical Винченцо ОРФЕО
Publication of RU2021118423A publication Critical patent/RU2021118423A/en

Links

Claims (15)

1. Гипертоническая офтальмологическая мазь, содержащая:1. Hypertonic ophthalmic ointment containing: - липофильную фазу;- lipophilic phase; - гидрофильную фазу, состоящую из воды, насыщенной хлоридом натрия и содержащей гиалуроновую кислоту или ее фармацевтически приемлемую соль;a hydrophilic phase consisting of water saturated with sodium chloride and containing hyaluronic acid or a pharmaceutically acceptable salt thereof; - эмульгирующий агент,- emulsifying agent, предназначенная для использования в лечении отека роговицы.intended for use in the treatment of corneal edema. 2. Мазь по п. 1, где липофильная фаза состоит из вазелина и парафина.2. Ointment according to claim 1, where the lipophilic phase consists of vaseline and paraffin. 3. Мазь по п. 1 или 2, где гидрофильная фаза дополнительно содержит регулятор рН.3. Ointment according to claim 1 or 2, wherein the hydrophilic phase further comprises a pH regulator. 4. Мазь по п. 3, где указанный регулятор рН представляет собой фосфатный буфер.4. An ointment according to claim 3, wherein said pH regulator is a phosphate buffer. 5. Мазь по любому из пп. 1-4, где эмульгирующий агент представляет собой эмульгирующий агент на основе ланолина.5. Ointment according to any one of paragraphs. 1-4, wherein the emulsifying agent is a lanolin-based emulsifying agent. 6. Мазь по любому из пп. 1-5, где гиалуроновая кислота или ее фармацевтически приемлемая соль имеет среднюю молекулярную массу в диапазоне от 20 кДа до 100 кДа.6. Ointment according to any one of paragraphs. 1-5, where hyaluronic acid or its pharmaceutically acceptable salt has an average molecular weight in the range from 20 kDa to 100 kDa. 7. Мазь по п. 6, где фармацевтически приемлемая соль гиалуроновой кислоты представляет собой гиалуронат натрия.7. An ointment according to claim 6 wherein the pharmaceutically acceptable salt of hyaluronic acid is sodium hyaluronate. 8. Мазь по любому из пп. 1-7, имеющая следующий состав:8. Ointment according to any one of paragraphs. 1-7, having the following composition:
Figure 00000001
Figure 00000001
9. Мазь по любому из пп. 1-8, имеющая вязкость в диапазоне от 150000 до 250000 сПз.9. Ointment according to any one of paragraphs. 1-8 having a viscosity in the range of 150,000 to 250,000 centipoise. 10. Мазь по любому из пп. 1-9, предназначенная для использования в лечении отека роговицы, вызванного операцией по удалению катаракты.10. Ointment according to any one of paragraphs. 1-9 for use in the treatment of corneal edema caused by cataract surgery.
RU2021118423A 2018-12-04 2019-11-28 Hypertonic ophthalmic ointment RU2021118423A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102018000010796 2018-12-04

Publications (1)

Publication Number Publication Date
RU2021118423A true RU2021118423A (en) 2023-01-09

Family

ID=

Similar Documents

Publication Publication Date Title
JP6527468B2 (en) Artificial tears containing sodium hyaluronate and carboxymethylcellulose
JP2006501133A5 (en)
AR089962A1 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR ELABORATION AND USE
EA201792559A1 (en) PHARMACEUTICAL COMPOSITIONS FOR LOCAL APPLICATION
BRPI0821683B8 (en) use of a parasympathetic agonist and a sympathetic antagonist or a sympathetic agonist to treat presbyopia, myopia, farsightedness, emmetropia and/or astigmatism, and/or to improve night or low light vision
RU2014146121A (en) METHODS FOR TREATING VASCULAR LEAF SYNDROME
RU2015143898A (en) OPHTHALMIC COMPOSITIONS FOR THE DELIVERY OF MEDICINES TO THE REAR SEGMENT OF THE EYE
RU2012103538A (en) COMPOSITIONS AND METHODS FOR INHIBITING JAK PATHWAY
EA201001439A1 (en) THREE-PHASE EMULSION (OPTIONS), METHOD FOR ITS PREPARATION AND APPLICATION
RU2014140885A (en) PHARMACEUTICAL COMPOSITION OF IBUPROFEN AND TRAMADOL FOR OPHTHALMIC USE
WO2017115238A1 (en) Compositions for the treatment of presbyopia
RU2008140117A (en) MONOMER TGF-β AND ITS APPLICATION
EA202091725A1 (en) OPHTHALMIC COMPOSITIONS CONTAINING BILASTINE, BETA-CYCLODEXTRIN AND AT LEAST ONE GREATING SUBSTANCE
RU2013107744A (en) BIMATOPROST AND THYMOLOL SOLUTIONS NOT CONTAINING CONSERVANTS
RU2009147168A (en) NEW ACTIVE SUBSTANCE FOR HEALING AND ITS USE
CN107496439A (en) Efficient and safe chitosan derivative-based disinfectant and preparation method thereof
RU2019139886A (en) THERAPEUTIC AGAINST DYSFUNCTION OF MEIBOMIUM GLANDS
EA201891730A1 (en) OPHTHALMOLOGICAL COMPOSITION FOR APPLICATION IN THE TREATMENT OF OPHTHALMOLOGICAL DISORDERS RELATED TO CHANGES OF CORNER-CONJUNCTIVE SURFACE
RU2691950C1 (en) Compositions and methods for inhibiting inflammation and diseases using alginic acid-based antimicrobial compound
MX2023009352A (en) Methods for ophthalmic delivery of roflumilast.
RU2021118423A (en) Hypertonic ophthalmic ointment
JP2017533228A5 (en)
WO2015094019A3 (en) Pharmaceutical preparation for preventing and treating progressive myopia
JP2021502337A5 (en)
RU2019118904A (en) EYE DISTRIBUTION AND PHARMACOKINETICS OF LIFITEGRAST COMPOSITIONS